Company intelligence / Profile preview

CeloNova BioSciences, Inc.

San Antonio, Texas, United Statesprnewswire.com ↗

Ownership: Private
Development stage: Commercial

Overview

The COBRA PzF stent met pre-specified performance goals for both the primary endpoint of target vessel failure and the secondary endpoint of angiographic late lumen loss at 9-months post-intervention in the PzF SHIELD clinical trial[7]. The company also received FDA approval for an IDE clinical trial for Oncozene embolic microspheres loaded with doxorubicin for hepatocellular carcinoma treatment[6].

Therapeutic areas: Women's HealthOncologyCardiovascular
Modalities: Medical device coatingsDrug-eluting microspheresCoronary stents
Industry: Surgical Medical Devices

Drug pipeline

1 asset

COBRA PzF NanoCoated Coronary Stent

Commercial

Indications: Coronary artery disease

Beyond the preview

Go deeper on CeloNova BioSciences, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CeloNova BioSciences, Inc..

Explore the full profile